Opexa Therapeutics Inc (OPXA.PH) Quote| Reuters.com
Edition:
United States

Opexa Therapeutics Inc (OPXA.PH)

OPXA.PH on Philadelphia Stock Exchange

3.88USD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$3.88
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
493
52-wk High
$4.70
52-wk Low
$1.83

OPXA.PH

Chart for OPXA.PH

About

Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $27.86
Shares Outstanding(Mil.): 6.98
Dividend: --
Yield (%): --

Financials

  OPXA.PH Industry Sector
P/E (TTM): -- 41.10 35.71
EPS (TTM): -1.63 -- --
ROI: -159.58 -6.56 14.23
ROE: -190.10 -5.98 15.43

BRIEF-Opexa Therapeutics Q1 loss per share $0.31

* Opexa therapeutics reports first quarter 2016 financial results and provides corporate update

May 12 2016

BRIEF-Opexa Therapeutics enters certain sales agreement, under which Co may sell shares in 'at-the-market' offering

* Says entered into certain sales agreement, under which co may sell shares in 'at-the-market' offering Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Mar 25 2016

BRIEF-Opexa expects top-line data for Abili-T trial to be available early in Q4

* Opexa therapeutics reports 2015 year end financial results and provides corporate update

Mar 15 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Edison Investment Research
$10.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.